Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) closed a registered direct offering of 16,129,033 common shares at $0.31 per share, generating approximately $5.0 million gross proceeds. The company concurrently issued unregistered warrants for up to 16,129,033 shares at a $0.31 exercise price, potentially raising an additional $5.0 million if exercised. The company amended existing warrants (2,142,854 shares) to a $0.31 exercise price; warrants’ exercisability and resale depend on stockholder approval and charter amendment timing. Net proceeds will be used primarily for working capital and general corporate purposes.
Positive
- $5.0M gross proceeds from registered direct offering
- Potential additional $5.0M if unregistered warrants fully exercised
- Registered sale executed under an effective Form S-3 shelf, enabling public resale of offered shares
Negative
- Issuance of 16,129,033 new shares creates immediate dilution
- Unregistered warrants for 16,129,033 shares could further dilute if exercised
- Amended warrants reduced exercise price from $2.26 to $0.31, increasing potential dilution
News Market Reaction – OTLK
In the Apr 24 session, OTLK gained 9.83%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.0% during that session. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Registered direct offering | Negative | -7.4% | Announced $5.0M registered direct deal with matching private-placement warrants. |
| Mar 25 | Offering closing | Negative | +1.0% | Closed $5.0M public offering of 20M shares plus 20M five-year warrants. |
| Mar 24 | Offering pricing | Negative | -38.1% | Priced $5.0M public offering at $0.25 per share with accompanying warrants. |
| Mar 23 | Proposed offering | Negative | -38.1% | Proposed best-efforts public offering of common stock and warrants under S-3. |
| May 23 | Offering pricing | Negative | -2.4% | Priced $13.0M public offering of stock with two five-year warrants per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Financing and offering announcements have typically drawn negative reactions: 4 of the last 5 offering-tag events saw declines, with some large selloffs.
Over the past year, Outlook Therapeutics has repeatedly used equity offerings and warrants to raise capital. Recent events include multiple $5.0 million raises in March–April 2026 and a $13.0 million public offering in May 2025. These offerings often paired common stock with five-year warrants and were conducted under an S-3 registration. Price reactions around such financings have skewed negative, with several double-digit declines, framing today’s closing of the registered direct offering and warrant repricing within an established dilution pattern.
Key Terms
registered direct offering financial
at-the-market financial
private placement financial
warrants financial
exercise price financial
certificate of incorporation regulatory
Regulation D regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering were approximately
The shares of common stock (but excluding the unregistered warrants and the shares of common stock issuable thereunder) were offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024 and became effective on April 5, 2024. The offering of the shares of common stock in the registered direct offering was made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and accompanying base prospectus relating to the registered direct offering has been filed with the SEC and is available for free on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
The unregistered warrants described above were offered and sold by the Company in a transaction not involving a public offering under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock issuable thereunder, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered warrants and the shares of common stock issuable thereunder may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
The Company also amended certain outstanding warrants to purchase up to an aggregate of 2,142,854 shares of the Company's common stock that were previously issued to an investor on January 16, 2025, with an exercise price of
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning.
These include statements concerning, among others, the use of proceeds from the offering, the potential exercise of the unregistered warrants, the Company’s receipt of stockholder approval for (i) the issuance of the shares of common stock issuable upon the exercise of the unregistered warrants, (ii) the amendment to the Company’s certificate of incorporation to increase the authorized shares of common stock, and (iii) the amendment of existing outstanding warrants held by an investor, the potential of ONS-5010/LYTENAVA™ as a treatment for retina diseases, the potential for ONS-5010 to receive approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with the use of proceeds from the registered direct offering and concurrent private placement, the receipt of the requisite stockholder approvals, the exercise of the unregistered warrants and the receipt of proceeds therefrom, developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by subsequent reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the global geopolitical conflict, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
